Aravis SA is a private equity and venture capital firm that focuses on investments in startup companies.
Business Model:
Revenue: $3.1M
Employees: 11-50
Address:
City:
State:
Zip:
Country:
Aravis SA is a private equity and venture capital firm that focuses on investments in startup companies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2004 | Kalypsys | Series B | 29M |
9/2008 | Telormedix | Series A | 0 |
4/2005 | Ikaria | Series A | 10M |
10/2002 | MerLion Pharma | Series A | 0 |
1/2009 | Synosia Therapeutics | Series B | 0 |
1/2012 | Telormedix | Series B | 0 |
10/2010 | MerLion Pharma | Series C | 0 |
7/2006 | Ambrx | Series C | 52M |
8/2004 | Evolva | Series A | 14.8M |
10/2010 | Synosia Therapeutics | Series C | 0 |
5/2009 | NovImmune | Venture Round | 0 |
12/2013 | Telormedix | Series B | 0 |
10/2004 | Miikana Therapeutics | Series A | 3M |
6/2006 | NovImmune | Series B | 0 |
5/2009 | Bird Rock Bio | Series A | 13M |
12/2006 | Evolva | Series A | 10.3M |
2/2007 | Omeros | Series E | 0 |
4/2009 | Ambrx | Series D | 10M |
10/2008 | S*Bio | Venture Round | 26M |
7/2009 | Symetis | Series B | 0 |
11/2004 | Symetis | Series A | 9.6M |
3/2014 | Bird Rock Bio | Series B | 0 |
10/2003 | Miikana Therapeutics | Series A | 4.3M |
2/2014 | Synaffix BV | Series A | - |
12/2009 | Evolva | Post-IPO Equity | 27.5M |
9/2004 | Nura | Series A | 9.5M |
10/2009 | Evolva | Series B | 27.8M |
12/2013 | Bellerophon Therapeutics | Series A | 0 |
3/2005 | Borean Pharma | Series A | 0 |
9/2008 | ImVisioN Therapeutics | Series A | 4.1M |
3/2014 | Bird Rock Bio | Series B | 0 |
2/2014 | Synaffix BV | Series A | - |
12/2013 | Bellerophon Therapeutics | Series A | 0 |
12/2013 | Telormedix | Series B | 0 |
1/2012 | Telormedix | Series B | 0 |
10/2010 | Synosia Therapeutics | Series C | 0 |
10/2010 | MerLion Pharma | Series C | 0 |
12/2009 | Evolva | Post-IPO Equity | 0 |
10/2009 | Evolva | Series B | 0 |
7/2009 | Symetis | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|